Halozyme Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	1,243	1,015	829.25	660.12	443.31	267.59
Revenue Growth (YoY)	31.19%	22.44%	25.62%	48.91%	65.66%	36.53%
Cost of Revenue	262.09	238.47	268.72	205.91	117.09	77.6
Gross Profit	980.76	776.86	560.53	454.21	326.23	189.99
Selling, General & Admin	172.31	154.34	149.18	121.63	50.32	45.74
Amortization of Goodwill & Intangibles	71.05	71.05	71.27	43.15	-	-
Operating Expenses	243.36	225.38	220.46	164.77	50.32	45.74
Operating Income	737.4	551.48	340.07	289.43	275.9	144.26
Interest Expense	-17.76	-18.1	-18.76	-16.95	-7.53	-20.38
Interest & Investment Income	20.77	12.83	10	3.88	3.36	5.43
EBT Excluding Unusual Items	740.41	546.21	331.31	276.36	271.74	129.3
Merger & Restructuring Charges	-	-	-	-21.9	-	-
Gain (Loss) on Sale of Investments	5.53	10.93	6.32	-2.83	-2.26	-
Asset Writedown	-	-	-2.5	-	-	-
Other Unusual Items	-	-	13.2	-2.71	-20.96	-
Pretax Income	745.94	557.13	348.33	248.92	248.52	129.3
Income Tax Expense	150.45	113.04	66.74	46.79	-154.19	0.22
Net Income	595.49	444.09	281.59	202.13	402.71	129.09
Net Income to Common	595.49	444.09	281.59	202.13	402.71	129.09
Net Income Growth	51.73%	57.71%	39.31%	-49.81%	211.97%	-
Shares Outstanding (Basic)	122	127	132	137	141	136
Shares Outstanding (Diluted)	126	129	134	141	147	141
Shares Change (YoY)	-3.31%	-3.56%	-4.56%	-4.21%	3.77%	-1.99%
EPS (Basic)	4.88	3.50	2.13	1.48	2.86	0.95
EPS (Diluted)	4.74	3.43	2.10	1.44	2.74	0.91
EPS Growth	56.68%	63.33%	45.83%	-47.45%	201.10%	-
Free Cash Flow	602.4	468.37	373.28	235.3	297.98	52.95
Free Cash Flow Per Share	4.80	3.62	2.78	1.67	2.03	0.37
Gross Margin	78.91%	76.51%	67.59%	68.81%	73.59%	71.00%
Operating Margin	59.33%	54.32%	41.01%	43.84%	62.24%	53.91%
Profit Margin	47.91%	43.74%	33.96%	30.62%	90.84%	48.24%
Free Cash Flow Margin	48.47%	46.13%	45.01%	35.64%	67.22%	19.79%
EBITDA	813.28	627.09	416.93	336.07	277.3	145.84
EBITDA Margin	65.44%	61.76%	50.28%	50.91%	62.55%	54.50%
D&A For EBITDA	75.89	75.61	76.86	46.64	1.4	1.58
EBIT	737.4	551.48	340.07	289.43	275.9	144.26
EBIT Margin	59.33%	54.32%	41.01%	43.84%	62.24%	53.91%
Effective Tax Rate	20.17%	20.29%	19.16%	18.80%	-	0.17%
Revenue as Reported	1,243	1,015	829.25	660.12	443.31	267.59

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.